Table 2.

Lp(a)-related risks of prevalent CAVD and development of CHD in a subcohort of MESA participants (n = 4593).^a

	Lp(a)-M (mg/dL)	Lp(a)-Cb (mg/dL)	Lp(a)-Pc (nmol/L)
Calcific aortic valve diseased
Upper 25th percentile	39.9	3.7	70
Estimated RR	1.49	1.48	1.49
95% CI	(1.27–1.74)	(1.26–1.73)	(1.27–1.75)
P value	<0.0001	<0.0001	<0.0001
Upper 15th cutoff value	59.7	6.9	119
Estimated RR	1.54	1.49	1.52
95% CI	(1.29–1.83)	(1.23–1.82)	(1.27–1.81)
P value	<0.0001	<0.0001	<0.0001
Incident coronary heart diseasee
Upper 25th percentile	39.9	3.7	70
Estimated HR	1.49	1.46	1.45
95% CI	(1.16–1.91)	(1.14–1.87)	(1.13–1.86)
P value	0.002	0.003	0.004
Upper 15th cutoff value	59.7	6.9	119
Estimated HR	1.40	1.76	1.41
95% CI	(1.05–1.88)	(1.33–2.34)	(1.06–1.87)
P value	0.02	<0.0001	0.02

The P values are in bold to highlight the significance.

^aAdjustments were made for age, sex, race/ethnicity, hypertension, smoking, education status, diabetes, LDL-C, and HDL-C.

^bThe LOQ for the Lp(a)-C assay was 3.0 mg/dL.

^cThe LOQ for the Lp(a)-P assay was 50 nmol/L.

^dRelative risk ratios (RRs) and 95% CI are presented for individuals in the upper 25th and 15th percentiles for each Lp(a) marker.

^eHazard ratios (HRs) and 95% CI are presented for individuals in upper 25th and 15th percentiles for each Lp(a) marker.